Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401)

Status: Recruiting
Location: See all (103) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 99
Healthy Volunteers: No
View:

• patients treated with asciminib in Japan.

Locations
Other Locations
Japan
Novartis Investigative Site
Recruiting
Akashi
Novartis Investigative Site
Recruiting
Akita
Novartis Investigative Site
Recruiting
Amagasaki
Novartis Investigative Site
Recruiting
Aomori
Novartis Investigative Site
Recruiting
Bunkyo Ku
Novartis Investigative Site
Recruiting
Chiba
Novartis Investigative Site
Recruiting
Fujioka City
Novartis Investigative Site
Recruiting
Fukaya
Novartis Investigative Site
Recruiting
Fukui
Novartis Investigative Site
Recruiting
Hakodate
Novartis Investigative Site
Recruiting
Hamamatsu
Novartis Investigative Site
Recruiting
Hamamatsu-city
Novartis Investigative Site
Recruiting
Hamamatsu-city
Novartis Investigative Site
Recruiting
Higashiibaraki-gun
Novartis Investigative Site
Recruiting
Hirakata-city
Novartis Investigative Site
Recruiting
Hiroshima
Novartis Investigative Site
Recruiting
Hiroshima
Novartis Investigative Site
Recruiting
Hitachi-city
Novartis Investigative Site
Recruiting
Ikoma
Novartis Investigative Site
Recruiting
Izumo
Novartis Investigative Site
Recruiting
Izunokuni
Novartis Investigative Site
Recruiting
Kamigyo-ku
Novartis Investigative Site
Recruiting
Kashihara City
Novartis Investigative Site
Recruiting
Kashiwa-city
Novartis Investigative Site
Recruiting
Kasugai
Novartis Investigative Site
Recruiting
Kawagoe
Novartis Investigative Site
Recruiting
Kinokawa
Novartis Investigative Site
Recruiting
Kisarazu
Novartis Investigative Site
Recruiting
Kitakyushu-city
Novartis Investigative Site
Recruiting
Kobe
Novartis Investigative Site
Recruiting
Kobe
Novartis Investigative Site
Recruiting
Kobe-city
Novartis Investigative Site
Recruiting
Kobe-city
Novartis Investigative Site
Recruiting
Koga
Novartis Investigative Site
Recruiting
Kurashiki-city
Novartis Investigative Site
Recruiting
Kyoto
Novartis Investigative Site
Recruiting
Kyoto
Novartis Investigative Site
Recruiting
Kyoto-city
Novartis Investigative Site
Recruiting
Maebashi
Novartis Investigative Site
Recruiting
Maebashi City
Novartis Investigative Site
Recruiting
Maebashi-city
Novartis Investigative Site
Recruiting
Maniwa
Novartis Investigative Site
Recruiting
Matsue
Novartis Investigative Site
Recruiting
Matsuyama
Novartis Investigative Site
Recruiting
Matsuyama-city
Novartis Investigative Site
Recruiting
Minato-ku
Novartis Investigative Site
Recruiting
Moriguchi
Novartis Investigative Site
Recruiting
Moriyama-city
Novartis Investigative Site
Recruiting
Muroran
Novartis Investigative Site
Recruiting
Nagahama
Novartis Investigative Site
Recruiting
Nagasaki-shi
Novartis Investigative Site
Recruiting
Nagoya
Novartis Investigative Site
Recruiting
Nagoya
Novartis Investigative Site
Recruiting
Nara
Novartis Investigative Site
Recruiting
Narita
Novartis Investigative Site
Recruiting
Natori
Novartis Investigative Site
Recruiting
Nishinomiya
Novartis Investigative Site
Recruiting
Nishinomiya-city
Novartis Investigative Site
Recruiting
Nishinomiya-city
Novartis Investigative Site
Recruiting
Okayama
Novartis Investigative Site
Recruiting
Okayama City
Novartis Investigative Site
Recruiting
Okayama-city
Novartis Investigative Site
Recruiting
Okayama-city
Novartis Investigative Site
Recruiting
Okayama-city
Novartis Investigative Site
Recruiting
Osaka
Novartis Investigative Site
Recruiting
Osaka
Novartis Investigative Site
Recruiting
Osaka
Novartis Investigative Site
Recruiting
Osaka
Novartis Investigative Site
Recruiting
Osaka Sayama
Novartis Investigative Site
Recruiting
Osaka-city
Novartis Investigative Site
Recruiting
Osaka-city
Novartis Investigative Site
Recruiting
Osaka-city
Novartis Investigative Site
Recruiting
Osaka-city
Novartis Investigative Site
Recruiting
Ota-city
Novartis Investigative Site
Recruiting
Saga-city
Novartis Investigative Site
Recruiting
Sakaide-city
Novartis Investigative Site
Recruiting
Saku-city
Novartis Investigative Site
Recruiting
Sano
Novartis Investigative Site
Recruiting
Sapporo
Novartis Investigative Site
Recruiting
Sapporo
Novartis Investigative Site
Recruiting
Sayama-city
Novartis Investigative Site
Recruiting
Shimajiri-gun
Novartis Investigative Site
Recruiting
Shinagawa Ku
Novartis Investigative Site
Recruiting
Suginami
Novartis Investigative Site
Recruiting
Suita
Novartis Investigative Site
Recruiting
Suita
Novartis Investigative Site
Recruiting
Sumoto
Novartis Investigative Site
Recruiting
Suwa
Novartis Investigative Site
Recruiting
Takarazuka
Novartis Investigative Site
Recruiting
Takayama
Novartis Investigative Site
Recruiting
Tenri
Novartis Investigative Site
Recruiting
Tokai
Novartis Investigative Site
Recruiting
Toyohashi
Novartis Investigative Site
Recruiting
Toyohashi
Novartis Investigative Site
Recruiting
Toyonaka-city
Novartis Investigative Site
Recruiting
Toyooka
Novartis Investigative Site
Recruiting
Tsu
Novartis Investigative Site
Recruiting
Tsu-city
Novartis Investigative Site
Recruiting
Tsukuba
Novartis Investigative Site
Recruiting
Tsuyama
Novartis Investigative Site
Recruiting
Wakayama
Novartis Investigative Site
Recruiting
Wakayama-city
Novartis Investigative Site
Recruiting
Yonago-city
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+81337978748
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: July 4, 2022
Estimated Completion Date: July 15, 2028
Participants
Target number of participants: 440
Treatments
Asciminib
Patients prescribed with Asciminib
Sponsors
Leads: Novartis Pharmaceuticals

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.